NCT06735508View on ClinicalTrials.gov

MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
NSCLC
Interventions
DRUG

mRNA Neoantigen Vaccine

mRNA Neoantigen Vaccine

DRUG

Adebrelimab

Adebrelimab is a programmed death-ligand 1 antibody.

Trial Locations (1)

510000

Guangdong Provincial People's Hospital, Guangzhou

All Listed Sponsors
collaborator

Shanghai Regenelead Therapies Co., Ltd.

INDUSTRY

lead

Guangdong Provincial People's Hospital

OTHER